Healthcare Private Placement and M&A Transactions Review Week Ending July 13, 2025

Nuclidium: The company raised EUR 84 million of Series B venture funding in a deal led by Angelini Ventures, Kurma Partners, Wellington Partners and NEVA SGR on July 10, 2025. Eurazeo, Vives Fund, DeepTech & Climate Fonds, Highlight Capital, Bayern Kapital, NRW.Bank, and other undisclosed investors also participated in the round. The company is a developer of novel radiopharmaceutical tracers designed for cancer diagnostics.

Actithera: The company raised $75.5 million of Series A venture funding in a deal led by M Ventures, 4BIO Capital, Sofinnova Partners and Hadean Ventures on July 9, 2025. Arkin Capital, Bioqube Ventures, Investinor, Innovestor and Surveyor Capital also participated in the round. The company is an operator of a molecular radio therapeutic business intended for biotechnology research services.

Neuros Medical: The company raised $56 million of Series D venture funding in a deal led by EQT Life Sciences on July 9, 2025. U.S. Venture Partners, Aperture Venture Partners, Osage University Partners, Amzak Health, Sectoral Asset Management and other undisclosed investors also participated in the round. The company is a developer of innovative therapies for chronic pain, specifically targeting the unmet needs of patients suffering from post-amputation pain.

Vitestro: The company is in process of raising EUR 30 million of Series B venture funding on July 7, 2025. The company is a developer of medical robotic devices designed for use in hospitals and clinical laboratories.

Aqtual: The company raised $31 million of Series B venture funding in a deal led by Manta Ray Ventures on July 10, 2025. BOLD Longevity Growth and Genoa Ventures, Yu Galaxy also participated in the round. The company is a developer of a novel analytical platform designed for cancer drug treatment.

Adela: The company raised $25.1 million of venture funding in the form of Convertible notes from F-Prime Capital on July 8, 2025. The company is an operator of a minimal residual disease monitoring platform intended to help in early cancer detection.

BlackLight Surgical: The company raised $10.8 million of venture funding from undisclosed investors on July 11, 2025. The company is a developer of a medical device designed to offer intra-operative and real-time diagnostic information.

Synfini: The company raised $8.9 million of venture funding in a deal led by JSL Health Capital on July 7, 2025. SRI Ventures, High Water Venture Partners, Foothill Ventures, Trust Ventures, Gaingels, WERU Investment, Ferocity Capital and Mana Ventures also participated in the round. The company is a developer of an artificial intelligence drug discovery platform designed to accelerate chemistry design, development, and synthesis.

BioSapien: The company raised $8 million of Pre-Series A venture funding through a combination of debt and equity on July 7, 2025, putting the company’s pre-money valuation at $15.6 million. $7.4 million of the equity funding was led by Global Ventures and Globivest with participation from SC Ventures, Golden Gate Ventures, SOSV, Hub71 and Dara Holdings. The company is a developer of a three-dimensional printed drug delivery platform designed to deliver medicines in a localized, sustained manner for cancer indications.

Piur Imaging: The company raised EUR 5.6 million of venture funding in a deal led by Aescuvest on July 9, 2025. The company is a developer of a tomographic ultrasound technology for vascular imaging.

GeodAlsics: The company raised EUR 5 million of Series A venture funding from The Vidi Group and other undisclosed investors on July 9, 2025. The company is a developer of a medtech business intended to offer AI-based clinical decision support modules.

Cumulus Neuroscience: The company raised GBP 3.3 million of venture funding from Clarendon Fund Managers, ACF Investors and Whiterock Finance as lead investor on July 8, 2025. Invest Northern Ireland also participated in the round. The company is a developer of an AI-based digital biomarker platform to aid in the diagnosis of neurodegeneration.

Somnair: The company raised $4.3 million of venture funding from MedStar Health, Wolf Point Capital and Jumpspace Ventures on July 7, 2025. Nexus NeuroTech Ventures and other undisclosed investors also participated in the round. The company is a developer of neurostimulation therapy intended to treat sleep apnea.

KromaTiD: The company raised $3.6 million of venture funding from undisclosed investors on July 10, 2025. The company is a developer of next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in the areas of oncology and rare diseases.

ScienceMachine: The company raised $3.5 million of venture funding in a deal led by Revent Capital and Nucleus Capital on July 9, 2025. The company is a developer of a biotechnology research system intended to accelerate biomedical discovery.

CardioWise: The company closed on $3 million of an undisclosed targeted amount of Series B venture funding on July 11, 2025, putting the company’s pre-money valuation at $30 million. The company is a developer of non-invasive cardiac CT imaging software designed for rapid quantitative analysis of left ventricular function.

Cobionix: The company raised $3 million of venture funding in a deal led by TitletownTech on July 9, 2025. Paul McBeth, Green Bay Packers and Lionstone Investments also participated in the round. The company is a developer of an autonomous robotics platform intended to address healthcare labor shortages.

Transposon: The company raised an undisclosed amount of venture funding from Alzheimers Drug Discovery Foundation on July 9, 2025. The company is an operator of a clinical-stage startup company intended to develop novel drugs for neurodegenerative diseases and diseases of aging.

Verona Pharma / Merck & Co.: The company reached a definitive agreement to be acquired by Merck & Co. for $10 billion on July 9, 2025. The company focuses on developing therapeutics for the treatment of respiratory diseases with unmet medical needs, such as chronic obstructive pulmonary disease, cystic fibrosis and other respiratory diseases, including asthma.

Nova Biomedical / Advanced Instruments: The company was acquired by Advanced Instruments, via its financial sponsor Patricia Industries, through a $2.2 billion LBO on July 10, 2025. The company’s product line ranges from hospital point-of-care measuring systems and hospital blood gas analyzers to biotech chemistry or cell analyzers and self-testing diabetes monitoring systems.

Aetion / Datavant: The company was acquired by Datavant, via its financial sponsors New Mountain Capital, Ardan Equity and Oxeon Partners, through an estimated $400 million LBO on July 11, 2025. The company is a developer of a healthcare analytics platform intended to offer real-world evidence to assess the safety, effectiveness, and value of medications and clinical interventions.

Novari Health / VitalHub: The company was acquired by VitalHub for $48.6 million on July 7, 2025. The company is a developer of an enterprise-scale access-to-care platform designed to improve workflows for patients, physicians, and administrators.

Paradigm Spine / Companion Spine: The company reached a definitive agreement to be acquired by Companion Spine for $19.2 million on July 7, 2025. The company is engaged in the development of a full non-fusion product portfolio of tissue-sparing devices for the treatment of spinal disorders.

Cargo Therapeutics / Concentra Biosciences: The company reached a definitive agreement to be acquired by Concentra Biosciences on July 8, 2025. Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients.

Akoya Biosciences / Quanterix: The company was acquired by Quanterix for an undisclosed amount on July 8, 2025. Akoya Biosciences Inc is a life sciences technology company delivering spatial phenotyping solutions.

Artinis Medical Systems / Gilde Healthcare: The company entered into a definitive agreement to be acquired by Gilde Healthcare through an LBO on July 8, 2025 for an undisclosed amount. The company is a developer of innovative medical research and quality assurance equipment in the field of near-infrared spectroscopy.

Avivia / Ofichem Groep: The company reached a definitive agreement to be acquired by Ofichem Groep for an undisclosed amount on July 9, 2025. The company is an operator of an independent pharmaceutical development business and a Contract Research Organization.

CareNexis / Aphora Health: The company was acquired by Aphora Health for an undisclosed amount on July 11, 2025. The company is a developer of a digital health platform designed to provide personalized health education and care recommendations.

FotoFinder / GHO Capital: The company entered into a definitive agreement to be acquired by GHO Capital through an LBO on July 8, 2025 for an undisclosed amount. The company specializes in skin cancer diagnostics and digital dermoscopy, as well as in hair consultation, psoriasis documentation and imaging in aesthetics.

LumiThera / Alcon: The company reached a definitive agreement to be acquired by Alcon for an undisclosed amount on July 7, 2025. The company is a developer of medical devices intended to prevent vision loss and blindness.

Profusa / NorthView Acquisition: The company acquired NorthView Acquisition through a reverse merger, resulting in the combined entity trading on the Nasdaq under the ticker symbol PFSA on July 13, 2025. The company is a developer of a healthcare platform designed to measure an individual’s biochemistry and provide the necessary data to manage chronic disease and health and wellness decisions.

Xealth / Samsung Electronics: The company reached a definitive agreement to be acquired by Samsung Electronics for an undisclosed amount on July 7, 2025. The company is an operator of a digital health platform that enables healthcare organizations to integrate, prescribe, and monitor digital health tools, programs, and services.